Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation-Reference-Cited by-同舟云学术

Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation

Published:2020-07-13 Issue:9 Volume:99 Page:2197-2199
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Apolito Vincenzo,Giaccone Luisa,Ferrero Simone,Larocca Alessandra,Cavallo Federica,Coscia Marta,Beggiato Eloise,Butera Sara,Martella Federica,Dainese Cristina,Cetani Giusy,Scaldaferri Matilde,Cattel Francesco,Boccadoro Mario,Ferrero Dario,Bruno Benedetto,Cerrano Marco^ORCID

Funder

This work was supported by a grant from Italfarmaco. Italfarmaco did not have access to data neither had any role in the preparation of the manuscript.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04180-6.pdf

Reference10 articles.

1. Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P (2018) From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 103:197–211. https://doi.org/10.3324/haematol.2017.174573

2. Tendas A, Marchesi F, Mengarelli A et al (2019) Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer 27:793–803. https://doi.org/10.1007/s00520-018-4594-2

3. Schmitt T, Goldschmidt H, Neben K, Freiberger A, Hüsing J, Gronkowski M, Thalheimer M, Pelzl LH, Mikus G, Burhenne J, Ho AD, Egerer G (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413–3420. https://doi.org/10.1200/JCO.2013.55.0095

4. Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T, Miyazawa Y, Matsumoto M, Sawamura M, Manaka A (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105:478–484. https://doi.org/10.1007/s12185-016-2152-6

5. Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308. https://doi.org/10.1007/s00520-016-3449-y

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation;Frontiers in Oncology;2023-11-21

2. A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation;Journal of Oncology Pharmacy Practice;2023-05-07

3. A Phase II Trial of Netupitant/Palonosetron for Prevention of Chemotherapy Induced Nausea/Vomiting in Patients Receiving BEAM Prior to Hematopoietic Cell Transplantation;2022-11-03

4. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission;Journal of Clinical Medicine;2022-03-16

5. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience;Supportive Care in Cancer;2021-08-04